

Sebastiaan Engelborghs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7326532/publications.pdf>

Version: 2024-02-01

308
papers

28,225
citations

15466

65
h-index

6282

158
g-index

356
all docs

356
docs citations

356
times ranked

25023
citing authors

#	ARTICLE	IF	CITATIONS
1	Adults with cerebral palsy and Alzheimer disease: a missing link?. <i>Developmental Medicine and Child Neurology</i> , 2022, 64, 284-284.	1.1	1
2	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. <i>Brain</i> , 2022, 145, 4056-4064.	3.7	19
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
4	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. <i>Toxicology Letters</i> , 2022, 356, 89-99.	0.4	8
5	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	4.1	9
6	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
7	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
8	A qualitative study with people with young-onset dementia and their family caregivers on advance care planning: A holistic, flexible, and relational approach is recommended. <i>Palliative Medicine</i> , 2022, 36, 964-975.	1.3	11
9	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12314.	1.2	15
10	Associations of Bilateral Vestibulopathy With Cognition in Older Adults Matched With Healthy Controls for Hearing Status. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 731.	1.2	16
11	Higher susceptibility to 60Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease. <i>Epilepsia</i> , 2022, 63, 2703-2715.	2.6	11
12	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. <i>Neurobiology of Aging</i> , 2021, 97, 145.e1-145.e4.	1.5	2
13	Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 99, 100.e17-100.e23.	1.5	5
14	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
15	Diagnostic Evaluation of Dementia. , 2021, , 31-55.		0
16	Lumbar Puncture: Consensus Guidelines. <i>Neuromethods</i> , 2021, , 129-135.	0.2	0
17	Melatonin levels in the Alzheimer's disease continuum: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 52.	3.0	37
18	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 25.	2.4	23

#	ARTICLE	IF	CITATIONS
19	CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports. <i>Neurology</i> , 2021, 96, 705-715.	1.5	7
20	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 313-324.	0.9	5
21	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
22	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1629-1642.	1.2	10
23	Vestibular Function in Older Adults With Cognitive Impairment: A Systematic Review. <i>Ear and Hearing</i> , 2021, 42, 1119-1126.	1.0	11
24	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23
25	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
26	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	1.7	16
27	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
28	Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2021, 156, 105421.	2.1	2
29	Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2021, 12, 707580.	1.3	21
30	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 104, 105.e1-105.e6.	1.5	8
31	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 623-639.	1.2	7
32	Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 693-704.	1.2	1
33	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. <i>Neurobiology of Aging</i> , 2021, 106, 307.e1-307.e7.	1.5	10
34	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 108, 99-109.	1.5	13
35	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2021, 28, 2147-2155.	1.7	20
36	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 746982.	1.7	12

#	ARTICLE	IF	CITATIONS
37	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	1.4	7
38	Cortical Auditory Evoked Potentials in Cognitive Impairment and Their Relevance to Hearing Loss: A Systematic Review Highlighting the Evidence Gap. <i>Frontiers in Neuroscience</i> , 2021, 15, 781322.	1.4	4
39	Development and analytical performance testing of a novel sTREM2 ELISA method to support drug development. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
40	Development and analytical characterization of novel tau Simoa assays targeting full-length tau in CSF and midline tau in CSF and plasma. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	Exploring Cognitive Frailty: Prevalence and Associations with Other Frailty Domains in Older People with Different Degrees of Cognitive Impairment. <i>Gerontology</i> , 2020, 66, 55-64.	1.4	17
42	Meanings of Care Convoys: The Structure, Function, and Adequacy of Care Networks Among Frail, Community-Dwelling Older Adults. <i>Qualitative Health Research</i> , 2020, 30, 583-597.	1.0	8
43	Stronger Correlations between Neurophysiological and Peripheral Disease Biomarkers Predict Better Prognosis in Two Severe Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 26.	1.0	5
44	Encephalitis associated with the SARS-CoV-2 virus: A case report. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2020, 22, 100821.	0.2	27
45	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
46	Impact of hearing loss and vestibular decline on cognition in Alzheimer's disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECKo). <i>BMJ Open</i> , 2020, 10, e039601.	0.8	16
47	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
48	Amyloid- β 1-43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 108.	3.0	17
49	Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. <i>Acta Neurologica Belgica</i> , 2020, 120, 1157-1163.	0.5	3
50	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	3.9	39
51	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.4	1
52	Biomarker counseling, disclosure of diagnosis, and follow-up in patients with mild cognitive impairment: A European survey of EADC centers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039026.	0.4	0
53	Recessive missense variants in VWA2 increase risk of developing Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039791.	0.4	0
54	ABCA7 mutations are major contributors to Alzheimer's disease in Belgian patients. <i>Alzheimer's and Dementia</i> , 2020, 16, e040227.	0.4	0

#	ARTICLE	IF	CITATIONS
55	ABCA7 PTC mutation carriers present with Alzheimer's disease pathology and cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e041513.	0.4	0
56	Cerebrospinal fluid amyloid status and affective symptoms in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e041961.	0.4	0
57	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042739.	0.4	0
58	3xTg Alzheimer's disease mice are more susceptible to induced seizures. <i>Alzheimer's and Dementia</i> , 2020, 16, e044096.	0.4	1
59	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853.	0.4	0
60	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.4	1
61	A family-based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. <i>Alzheimer's and Dementia</i> , 2020, 16, e047212.	0.4	2
62	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
63	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 58.	3.0	56
64	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. <i>Acta Neuropathologica</i> , 2020, 139, 1001-1024.	3.9	46
65	Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm. <i>NeuroImage: Clinical</i> , 2020, 26, 102243.	1.4	25
66	Depressive Symptoms in the Elderly: An Early Symptom of Dementia? A Systematic Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 34.	1.6	43
67	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 48.	1.6	5
68	Comparing Advance Care Planning in Young-Onset Dementia in the USA vs Belgium: Challenges Partly Related to Societal Context. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 851-857.	1.2	10
69	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
70	Title is missing!. , 2020, 17, e1003289.		0
71	Title is missing!. , 2020, 17, e1003289.		0
72	Title is missing!. , 2020, 17, e1003289.		0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 17, e1003289.		0
74	Title is missing!. , 2020, 17, e1003289.		0
75	Title is missing!. , 2020, 17, e1003289.		0
76	Title is missing!. , 2020, 17, e1003289.		0
77	¹⁸ F-FDG PET, the early phases and the delivery rate of ¹⁸ F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against ¹⁵ O-H ₂ O PET. Alzheimer's and Dementia, 2019, 15, 1172-1182.	0.4	33
78	Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. Alzheimer's Research and Therapy, 2019, 11, 73.	3.0	20
79	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. Frontiers in Neuroscience, 2019, 13, 757.	1.4	22
80	Limited engagement in, yet clear preferences for advance care planning in young-onset dementia: An exploratory interview-study with family caregivers. Palliative Medicine, 2019, 33, 1166-1175.	1.3	20
81	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	0.5	9
82	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
83	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. Journal of Alzheimer's Disease, 2019, 69, 989-1001.	1.2	14
84	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
85	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neurolmage: Clinical, 2019, 23, 101846.	1.4	18
86	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
87	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Journal of Alzheimer's Disease, 2019, 68, 1151-1159.	1.2	9
88	Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review. Alzheimer's Research and Therapy, 2019, 11, 21.	3.0	113
89	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
90	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. Acta Neuropathologica, 2019, 137, 901-918.	3.9	37

#	ARTICLE	IF	CITATIONS
91	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. <i>NeuroImage: Clinical</i> , 2019, 22, 101771.	1.4	108
92	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141.	1.5	23
93	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
94	P4525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1515.	0.4	0
95	O503: ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.4	0
96	ICP130: ICOPROBRAIN DM: A NEW METHOD FOR HIPPOCAMPUS AND BRAIN LOBE SEGMENTATION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P107.	0.4	0
97	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70
98	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	1.5	37
99	CFR Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 941-947.	1.3	25
100	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. <i>Neurobiology of Aging</i> , 2018, 67, 84-94.	1.5	17
101	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
102	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 31.	3.0	42
103	Extended FTL pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 7.	3.0	10
104	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1199-1209.	1.2	69
105	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2018, 135, 827-837.	3.9	68
106	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
107	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	1.5	19
108	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215

#	ARTICLE	IF	CITATIONS
109	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
110	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	1.5	16
111	P2-270: INCREASED CSF AMYLOID- β 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P780.	0.4	0
112	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1161.	0.4	0
113	P2-228: PREANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P755.	0.4	0
114	O4-01-01: IN-DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1400.	0.4	0
115	F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P204.	0.4	0
116	P3-128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P1116.	0.4	0
117	P3-409: PERFORMANCE EVALUATION OF AUTOMATIC BRAIN MRI SUBSTRUCTURE SEGMENTATION WITH ICOBRAIN. <i>Alzheimer's and Dementia</i> , 2018, 14, P1260.	0.4	0
118	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 373-381.	1.2	12
119	F1-02-02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. <i>Alzheimer's and Dementia</i> , 2018, 14, P201.	0.4	0
120	F1-02-01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO $A\beta$, APOE ϵ 4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P201.	0.4	0
121	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	3.0	64
122	Randomized controlled trial to evaluate a prevention program for frail community-dwelling older adults: a D-SCOPE protocol. <i>BMC Geriatrics</i> , 2018, 18, 194.	1.1	13
123	P2-458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P895.	0.4	0
124	F1-02-03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P202.	0.4	0
125	Callosal circularity as an early marker for Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 516-526.	1.4	12
126	Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. <i>Neurobiology of Aging</i> , 2018, 69, 292.e7-292.e14.	1.5	18

#	ARTICLE	IF	CITATIONS
127	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1509-1522.	1.2	17
128	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
129	Detecting frail, older adults and identifying their strengths: results of a mixed-methods study. <i>BMC Public Health</i> , 2018, 18, 191.	1.2	41
130	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 85.	3.0	69
131	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	1.5	15
132	Identifying frailty risk profiles of home-dwelling older people: focus on sociodemographic and socioeconomic characteristics. <i>Aging and Mental Health</i> , 2017, 21, 1031-1039.	1.5	36
133	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. <i>Neurobiology of Aging</i> , 2017, 51, 177.e9-177.e16.	1.5	60
134	Selecting A β isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. <i>Biomarkers in Medicine</i> , 2017, 11, 169-178.	0.6	11
135	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A β ⁴² /A β ⁴⁰ ratio. , 2017, 13, 885-892.		52
136	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1437-1449.	1.2	28
137	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1013-1023.	0.4	33
138	Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion. <i>JAMA Neurology</i> , 2017, 74, 445.	4.5	56
139	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	3.9	53
140	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
141	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	1.5	27
142	Validation of the Semiquantitative Static SUVR Method for ¹⁸ F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1483-1489.	2.8	29
143	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113
144	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108

#	ARTICLE	IF	CITATIONS
145	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	1.1	87
146	Severe bilateral subdural hematomas as a complication of diagnostic lumbar puncture for possible Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 152, 95-96.	0.6	5
147	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. <i>Acta Neurologica Belgica</i> , 2017, 117, 811-819.	0.5	15
148	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <i>Acta Neurologica Belgica</i> , 2017, 117, 591-602.	0.5	90
149	[P4075]: THE <i>MAPT</i> P.ARG406TRP IS A FOUNDER MUTATION IN BELGIUM AND PRESENTS WITH AN ALZHEIMER DISEASE DEMENTIA-LIKE PHENOTYPE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1286.	0.4	1
150	[P4069]: A PROSPECTIVE NEUROGENETIC STUDY ON EARLY-ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1284.	0.4	0
151	[P1237]: DIFFERENTIAL ROLE OF CSF FATTY ACID BINDING PROTEIN 3, β -SYNUCLEIN AND ALZHEIMER'S DISEASE CORE BIOMARKERS IN LEWY BODY DISORDERS AND ALZHEIMER'S DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P334.	0.4	0
152	[P2363]: EARLY FRAME 18F-AV45 AND 18F-FDG-PET AS PROXIES OF CBF: COMPARISON TO 15O-H ₂ O PET DATA. <i>Alzheimer's and Dementia</i> , 2017, 13, P763.	0.4	2
153	[P4239]: FDG-PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER'S DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1366.	0.4	0
154	[P1289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A β 2 OR AMYLOID-PET) IN THE EMIFAD BIOMARKER DISCOVERY COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P361.	0.4	0
155	[P1387]: CHARACTERIZATION OF SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P414.	0.4	0
156	[P2116]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P651.	0.4	0
157	[P2211]: AMYLOID β 242 (A β 242) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK4 FOR AD POPULATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P690.		0
158	[O21305]: DELETERIOUS <i>ABCA7</i> MUTATIONS CONTRIBUTE TO EARLY-ONSET ALZHEIMER'S DISEASE AND ARE SUBJECT TO TRANSCRIPT RESCUE MECHANISMS. <i>Alzheimer's and Dementia</i> , 2017, 13, P589.	0.4	0
159	The Cerebrospinal Fluid A β 1-42/A β 1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 561-576.	1.2	82
160	Multicenter Analytical Validation of A β 240 Immunoassays. <i>Frontiers in Neurology</i> , 2017, 8, 310.	1.1	10
161	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. <i>BMC Neurology</i> , 2017, 17, 170.	0.8	70
162	No added diagnostic value of non-phosphorylated tau fraction (p-tau _{el}) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 49.	3.0	11

#	ARTICLE	IF	CITATIONS
163	Differential role of CSF fatty acid binding protein 3, β -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 52.	3.0	101
164	A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease. <i>PLoS ONE</i> , 2017, 12, e0189155.	1.1	14
165	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1523-1538.	1.2	46
166	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 97-106.	1.2	20
167	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 383-395.	1.2	47
168	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 159-170.	1.2	23
169	EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 53-58.	1.2	13
170	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 19-35.	1.2	35
171	<sc>TREM</sc> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	3.3	392
172	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1321-1333.	1.2	44
173	P2-299: Brief Neuropsychological Screening Tests for the Detection of Alzheimer's Disease in an Early Phase: A Systematic Review. , 2016, 12, P748-P748.		0
174	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. <i>Alzheimer's and Dementia</i> , 2016, 12, P1059.	0.4	0
175	P4-194: Blood Flow-Independent Quantification of [18F]-AV45 PET Using Model-Based Kinetics With a Metabolite-Corrected Arterial Input Function. , 2016, 12, P1097-P1098.		0
176	P1-176: CSF Exploratory Biomarker Study for (DIFFERENTIAL) Diagnosis of Frontotemporal Lobar Degeneration. <i>Alzheimer's and Dementia</i> , 2016, 12, P471.	0.4	0
177	P1-320: Volumetric Brain MRI of Different Regions, Including The Hippocampus, in The Alzheimer's Disease Spectrum: A Systematic Review. <i>Alzheimer's and Dementia</i> , 2016, 12, P547.	0.4	0
178	P1-407: Cognitive Frailty: A New Domain Added to The Comprehensive Frailty Assessment. <i>Alzheimer's and Dementia</i> , 2016, 12, P590.	0.4	1
179	P2-153: Diagnostic Performance of Non-Phosphorylated TAU Fraction (PTAU REL) in CSF as Biomarker for Differential Dementia Diagnosis. , 2016, 12, P672-P673.		0
180	P3-258: Resting State Functional Mri in Alzheimer's Disease: an Innovative Approach for Robust Extraction of the Default Mode Network. <i>Alzheimer's and Dementia</i> , 2016, 12, P930.	0.4	0

#	ARTICLE	IF	CITATIONS
181	P4-120: Increased CSF Levels of Biomarkers for Neurodegeneration in FTL-GRN Mutation Carriers. <i>Alzheimer's and Dementia</i> , 2016, 12, P1058.	0.4	0
182	O1-11-02: Combination of Cerebrospinal Fluid H-FABP and Core Alzheimer's Disease Biomarkers Improves the Differential Diagnosis of Neurodegenerative Disorders. , 2016, 12, P201-P202.		1
183	O4-09-03: Eeg Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Alzheimer's and Dementia</i> , 2016, 12, P354.	0.4	0
184	P1-170: A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. , 2016, 12, P467-P468.		0
185	P4-314: Discordance Between Amyloid-PET and CSF Amyloid- β for Diagnosing Alzheimer's Disease in a Clinical Setting. <i>Alzheimer's and Dementia</i> , 2016, 12, P1154.	0.4	0
186	P4-322: CSF Biomarkers to Predict Rate of Cognitive Decline in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P1157.	0.4	0
187	P4-324: Plasma Neurofilament Light Concentration Predicts Long-Term Outcome an Acute Stroke. <i>Alzheimer's and Dementia</i> , 2016, 12, P1158.	0.4	0
188	Phenotypic characteristics of Alzheimer patients carrying an <i>ABCA7</i> mutation. <i>Neurology</i> , 2016, 86, 2126-2133.	1.5	29
189	Profiling the dynamics of CSF and plasma $A\beta$ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 202-212.	1.8	50
190	SolCos model-based individual reminiscence for older adults with mild to moderate dementia in nursing homes: a randomized controlled intervention study. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2016, 23, 568-575.	1.2	35
191	Mutated <i>CTSF</i> in adult-onset neuronal ceroid lipofuscinosis and FTD. <i>Neurology: Genetics</i> , 2016, 2, e102.	0.9	21
192	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	1.2	18
193	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. <i>Neuroscience Letters</i> , 2016, 629, 160-164.	1.0	34
194	P4-159: Screening and Recruitment Experience When Using Biomarker-Based Population Definition in Alzheimer's Disease Studies. , 2016, 12, P1075-P1076.		0
195	P3-209: Impact of Biomarkers On Diagnostic Confidence in Clinical Assessment of Patients with Suspected Alzheimer's Disease and High Diagnostic Uncertainty: An EADC Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P904.	0.4	0
196	Impact of frequent cerebrospinal fluid sampling on $A\beta$ levels: systematic approach to elucidate influencing factors. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 21.	3.0	11
197	Validation of soluble amyloid- β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016, 137, 112-121.	2.1	17
198	Clinical features of <i>TBK1</i> carriers compared with <i>C9orf72</i> , <i>GRN</i> and non-mutation carriers in a Belgian cohort. <i>Brain</i> , 2016, 139, 452-467.	3.7	86

#	ARTICLE	IF	CITATIONS
199	Next Generation Brain Health Depends on Early Alzheimer Disease Diagnosis: From a Timely Diagnosis to Future Population Screening. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 452-453.	1.2	16
200	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
201	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
202	O4-11-03: Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer's disease. , 2015, 11, P296-P297.		0
203	P4-232: A monoclonal antibody-based elisa for neurogranin. , 2015, 11, P869-P869.		1
204	P4-248: Resting state functional MRI as a possible biomarker for Alzheimer's disease: An innovative approach for robust extraction of the default mode network. , 2015, 11, P876-P876.		0
205	Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 937-948.	1.2	50
206	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
207	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. <i>Acta Neuropathologica Communications</i> , 2015, 3, 68.	2.4	13
208	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. <i>Frontiers in Neurology</i> , 2015, 6, 138.	1.1	44
209	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , 2015, 6, 179.	1.1	348
210	P4-249: Admetrix: A new method for atrophy quantification in Alzheimer's disease. , 2015, 11, P876-P876.		1
211	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
212	P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients. , 2015, 11, P626-P626.		0
213	P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease. , 2015, 11, P854-P854.		0
214	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid- β^2 Isoforms for Early and Differential Dementia Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 813-822.	1.2	82
215	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1039-1043.	1.2	15
216	Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 864-869.	1.3	29

#	ARTICLE	IF	CITATIONS
217	Association of Cerebrospinal Fluid Prion Protein Levels and the Distinction Between Alzheimer Disease and Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2015, 72, 267.	4.5	69
218	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. <i>Acta Neurologica Belgica</i> , 2015, 115, 547-555.	0.5	7
219	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284
220	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 7.	3.0	47
221	Tau Monoclonal Antibody Generation Based on Humanized Yeast Models. <i>Journal of Biological Chemistry</i> , 2015, 290, 4059-4074.	1.6	21
222	Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , 2015, 19, 818-828.	1.5	19
223	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
224	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. <i>Lancet Neurology</i> , The, 2015, 14, 814-822.	4.9	124
225	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	1.5	30
226	A 22â€single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid A β ₄₂ . <i>Alzheimer's and Dementia</i> , 2015, 11, 1452-1460.	0.4	96
227	Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , 2015, 19, 247-257.	1.5	32
228	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	1.5	34
229	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
230	Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2015, 61, 734-743.	1.5	53
231	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. <i>Molecular Neurodegeneration</i> , 2015, 10, 30.	4.4	46
232	C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1461-1469.	0.4	117
233	Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort. <i>Neurology</i> , 2015, 85, 2116-2125.	1.5	151
234	Apraxic agraphia following thalamic damage: Three new cases. <i>Brain and Language</i> , 2015, 150, 153-165.	0.8	4

#	ARTICLE	IF	CITATIONS
235	Techniques, Contraindications, and Complications of CSF Collection Procedures. , 2015, , 35-57.		12
236	Depression in Mild Cognitive Impairment is associated with Progression to Alzheimer's Disease: A Longitudinal Study. Journal of Alzheimer's Disease, 2014, 42, 1239-1250.	1.2	107
237	Poststroke depression and its multifactorial nature: Results from a prospective longitudinal study. Journal of the Neurological Sciences, 2014, 347, 159-166.	0.3	67
238	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
239	O1-04-04: ANALYSIS OF SQSTM1 IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE. , 2014, 10, P135-P136.		0
240	Risk Factors for Poststroke Depression. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 147-158.	1.2	126
241	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
242	Biobanking of CSF: International standardization to optimize biomarker development. Clinical Biochemistry, 2014, 47, 288-292.	0.8	97
243	Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. Acta Clinica Belgica, 2014, 69, 17-24.	0.5	44
244	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
245	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
246	Increased CSF α -synuclein levels in Alzheimer's disease: Correlation with tau levels. Alzheimer's and Dementia, 2014, 10, S290-8.	0.4	69
247	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2691-2700.	1.5	70
248	Validation of the AD-CSF-Index in Autopsy-Confirmed Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2014, 41, 903-909.	1.2	26
249	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 819-833.	1.2	53
250	P1-053: OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE. , 2014, 10, P322-P323.		0
251	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. International Journal of Geriatric Psychiatry, 2013, 28, 265-275.	1.3	50
252	Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Revue Neurologique, 2013, 169, 709-714.	0.6	19

#	ARTICLE	IF	CITATIONS
253	A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	1.1	247
254	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
255	Distinct Clinical Characteristics of C9orf72 Expansion Carriers Compared With GRN, MAPT, and Nonmutation Carriers in a Flanders-Belgian FTLD Cohort. <i>JAMA Neurology</i> , 2013, 70, 365.	4.5	85
256	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	4.5	374
257	Longitudinal Stability of Cerebrospinal Fluid Biomarker Levels: Fulfilled Requirement for Pharmacodynamic Markers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 807-822.	1.2	35
258	Cerebrospinal Fluid A β ¹⁻⁴⁰ Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 759-767.	1.2	79
259	Amyloid Pathology Influences A β ¹⁻⁴² Cerebrospinal Fluid Levels in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 137-146.	1.2	45
260	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 117-131.	1.2	40
261	The genetics and neuropathology of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2012, 124, 353-372.	3.9	242
262	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 65-73.	0.4	271
263	Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. <i>Neurobiology of Aging</i> , 2012, 33, 1004.e17-1004.e20.	1.5	32
264	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. <i>Molecular Neurodegeneration</i> , 2012, 7, 3.	4.4	77
265	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	0.6	280
266	The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. <i>Journal of the Neurological Sciences</i> , 2012, 322, 197-199.	0.3	9
267	The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer's Disease. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 135-141.	1.6	22
268	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. <i>Lancet Neurology</i> , The, 2012, 11, 54-65.	4.9	565
269	No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2011, 32, 754-755.	1.5	42
270	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708

#	ARTICLE	IF	CITATIONS
271	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. <i>Brain</i> , 2011, 134, 808-815.	3.7	110
272	Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1186-1195.	1.3	18
273	Follow-Up Study of Susceptibility Loci for Alzheimer's Disease and Onset Age Identified by Genome-Wide Association. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1169-1175.	1.2	33
274	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. <i>Archives of Neurology</i> , 2010, 67, 949.	4.9	407
275	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010, 31, 1867-1876.	1.5	63
276	O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease. , 2010, 6, S73-S74.		0
277	Clinical heterogeneity in 3 unrelated families linked to <i>VCP</i> p.Arg159His. <i>Neurology</i> , 2009, 73, 626-632.	1.5	84
278	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2009, 65, 603-609.	2.8	195
279	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. <i>Human Mutation</i> , 2009, 30, 1054-1061.	1.1	58
280	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1094-1099.	9.4	2,155
281	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	9.4	2,697
282	Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P. <i>Neurochemistry International</i> , 2009, 55, 214-218.	1.9	144
283	No correlation between time-linked plasma and CSF A β 2 levels. <i>Neurochemistry International</i> , 2009, 55, 820-825.	1.9	53
284	The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. <i>Neurochemistry International</i> , 2008, 52, 1052-1060.	1.9	72
285	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008, 29, 1143-1159.	1.5	217
286	No association of CSF biomarkers with APOE ϵ 4, plaque and tangle burden in definite Alzheimer's disease. <i>Brain</i> , 2007, 130, 2320-2326.	3.7	110
287	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. <i>Archives of Neurology</i> , 2007, 64, 1436.	4.9	143
288	Neuropsychological and behavioural correlates of CSF biomarkers in dementia. <i>Neurochemistry International</i> , 2006, 48, 286-295.	1.9	61

#	ARTICLE	IF	CITATIONS
289	Dose dependent effect of APOE ϵ 4 on behavioral symptoms in frontal lobe dementia. <i>Neurobiology of Aging</i> , 2006, 27, 285-292.	1.5	64
290	Behavioural and neuropsychological correlates of frontal lobe features in dementia. <i>Psychological Medicine</i> , 2006, 36, 1173-1182.	2.7	29
291	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. <i>Nature</i> , 2006, 442, 920-924.	13.7	1,386
292	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. <i>Brain</i> , 2006, 129, 841-852.	3.7	88
293	The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 70-79.	1.3	78
294	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1028-1037.	1.3	104
295	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005, 14, 3281-3292.	1.4	156
296	Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 365-370.	1.3	49
297	5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 1108-1109.	1.3	3
298	Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. <i>Neurochemical Research</i> , 2003, 28, 1145-1150.	1.6	69
299	Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1148-1151.	0.9	110
300	Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis. <i>Acta Neurologica Belgica</i> , 2003, 103, 99-102.	0.5	4
301	Headache As Only Symptom in Multiple Cervical Artery Dissection. <i>Headache</i> , 2001, 41, 509-511.	1.8	12
302	Biological and genetic markers of sporadic Alzheimer's disease. <i>Acta Medica Okayama</i> , 2001, 55, 55-63.	0.1	1
303	Loss of Psychic Self-Activation After Paramedian Bithalamic Infarction. <i>Stroke</i> , 2000, 31, 1762-1765.	1.0	81
304	Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. <i>Neuroscience Research Communications</i> , 2000, 26, 193-206.	0.2	10
305	Unchanged levels of interleukins, neopterin, interferon- γ and tumor necrosis factor- α in cerebrospinal fluid of patients with dementia of the Alzheimer type. <i>Neurochemistry International</i> , 1999, 34, 523-530.	1.9	66
306	Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. <i>Arzneimittelforschung</i> , 1998, 48, 713-6.	0.5	4

#	ARTICLE	IF	CITATIONS
307	Functional anatomy, vascularisation and pathology of the human thalamus. Acta Neurologica Belgica, 1998, 98, 252-65.	0.5	25
308	Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study. SSRN Electronic Journal, 0, , .	0.4	0